The Importance of Testing for MSI Status in Gastric CancersMay 7th 2018
Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of testing for microsatellite instability-high (MSI-H) status in patients with gastric cancers.
Associations of PD-1 and PD-L1 Expression, MMR Status, and Prognosis in Esophageal and Gastric CancerFebruary 2nd 2018
Maria Svensson, MD, Lund University, discusses associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma.<br />
Ramucirumab/Durvalumab Combo Produces Antitumor Activity in Gastric, GEJ CancerJanuary 25th 2018
According to findings presented at the 2018 Gastrointestinal Cancers Symposium, the combination of the VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti–PD-L1 agent durvalumab (Imfinzi) demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Avelumab Fails to Improve OS in Phase III Gastric Cancer TrialNovember 30th 2017
In findings from the phase III JAVELIN Gastric 300 trial, survival was not improved with the anti–PD-L1 agent avelumab compared with chemotherapy in previously treated patients with gastric or gastroesophageal junction adenocarcinoma.<br />